![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
What if cancer wan't defined by it's location in the body? Whether it was found in the liver, kidney, lung or blood, what if a specific genetic mutation caused the cancerous cells to grow? A new study is being sponsored by the American Society of Clinical Oncology (ASCO) called TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer.
The study is being done in collaboration with seven pharmaceutical companies (AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme Corp., Pfizer) with up to 16 different drugs.
Patients with Non-Hodgkins Lymphoma, Non-Hodgkin and Multiple Myeloma and Advanced Solid Tumors will be included in the study which will be open at many trial sites. Patients will be tested for their disease genetics and will then be separated into groups with the same genetic mutations. Each group will receive a drug that specifically targets those mutations.
| Group 1 (VEGFR)
Participants receive axitinib - dosage, frequency and duration per label VEGFR mutation, amplification or overexpression) |
Drug: Axitinib
Other Name: Inlyta
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 2 (Bcr-abl, SRC, LYN, LCK)
Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations |
Drug: Bosutinib
Other Name: Bosulif
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 3 (ALK, ROS1, MET)
Participants receive crizotinib - dosage, frequency and duration per label ALK, ROS1, MET mutations |
Drug: Crizotinib
Other Name: Xalkori |
| Group 4 (CDKN2A/p16, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label CDKN2A/p16 loss, CDK4, CDK6 amplifications |
Drug: Palbociclib
Other Name: Ibrance
( Cyclin-Dependent Kinases (CDK) Inhibitor ) |
| Group 5 (CSF1R, PDGFR, VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label CSF1R, PDGFR, VEGFR mutations |
Drug: Sunitinib
Other Name: Sutent |
| Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label mTOR, TSC mutations |
Drug: Temsirolimus
Other Name: Torisel
( Mammalian Target of Rapamycin (mTOR) Inhibitor ) |
| Group 7 (EGFR)
Participants receive erlotinib - dosage, frequency and duration per label EGFR mutations |
Drug: Erlotinib
Other Name: Tarceva
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label (ERBB2 amplifications) |
Drug: Trastuzumab and Pertuzumab
Other Name: Herceptin and Perjeta
( Immunotherapy , Monoclonal Antibody ) |
| Group 9 (BRAFV600E)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label BRAFV600E mutations |
Drug: Vemurafenib and Cobimetinib
Other Name: Zelboraf and Cotellic
( Bruton's Tyrosine Kinase (BTK) Inhibitor ) ( MEK Inhibitor )
|
| Group 10 (PTCH1)
Participants receive vismodegib - dosage, frequency and duration per label PTCH1 deletion or inactivating mutations |
Drug: Vismodegib
Other Name: Erivedge |
| Group 11 (KRAS, NRAS and BRAF)
Participants receive cetuximab - dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype |
Drug: Cetuximab
Other Name: Erbitux
( Immunotherapy , Monoclonal Antibody ) |
| Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)
Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations |
Drug: Dasatinib
Other Name: Sprycel
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 13 (RET,VEGFR1/2/3,KIT,PDGFR?,RAF-1,BRAF
Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR?, RAF-1, BRAF mutations/amplifications |
Drug: Regorafenib
Other Name: Stivarga |
| Group 14 (BRCA1/BRCA2; ATM)
Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions |
Drug: Olaparib
Other Name: Lynparza |
| Group 15 (POLE/POLD1;high mutational load)
Participants receive pembrolizumab- dosage, frequency and duration per label Note: high mutational load defined per protocol |
Drug: Pembrolizumab
Other Name: Keytruda |
Learn more and find the closest trial site here:
TUPAC Clinical Trial
To find eligible clinical trials for your myeloma, click here: Find Myeloma Clinical Trials on SparkCures
What if cancer wan't defined by it's location in the body? Whether it was found in the liver, kidney, lung or blood, what if a specific genetic mutation caused the cancerous cells to grow? A new study is being sponsored by the American Society of Clinical Oncology (ASCO) called TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer.
The study is being done in collaboration with seven pharmaceutical companies (AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme Corp., Pfizer) with up to 16 different drugs.
Patients with Non-Hodgkins Lymphoma, Non-Hodgkin and Multiple Myeloma and Advanced Solid Tumors will be included in the study which will be open at many trial sites. Patients will be tested for their disease genetics and will then be separated into groups with the same genetic mutations. Each group will receive a drug that specifically targets those mutations.
| Group 1 (VEGFR)
Participants receive axitinib - dosage, frequency and duration per label VEGFR mutation, amplification or overexpression) |
Drug: Axitinib
Other Name: Inlyta
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 2 (Bcr-abl, SRC, LYN, LCK)
Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations |
Drug: Bosutinib
Other Name: Bosulif
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 3 (ALK, ROS1, MET)
Participants receive crizotinib - dosage, frequency and duration per label ALK, ROS1, MET mutations |
Drug: Crizotinib
Other Name: Xalkori |
| Group 4 (CDKN2A/p16, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label CDKN2A/p16 loss, CDK4, CDK6 amplifications |
Drug: Palbociclib
Other Name: Ibrance
( Cyclin-Dependent Kinases (CDK) Inhibitor ) |
| Group 5 (CSF1R, PDGFR, VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label CSF1R, PDGFR, VEGFR mutations |
Drug: Sunitinib
Other Name: Sutent |
| Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label mTOR, TSC mutations |
Drug: Temsirolimus
Other Name: Torisel
( Mammalian Target of Rapamycin (mTOR) Inhibitor ) |
| Group 7 (EGFR)
Participants receive erlotinib - dosage, frequency and duration per label EGFR mutations |
Drug: Erlotinib
Other Name: Tarceva
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label (ERBB2 amplifications) |
Drug: Trastuzumab and Pertuzumab
Other Name: Herceptin and Perjeta
( Immunotherapy , Monoclonal Antibody ) |
| Group 9 (BRAFV600E)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label BRAFV600E mutations |
Drug: Vemurafenib and Cobimetinib
Other Name: Zelboraf and Cotellic
( Bruton's Tyrosine Kinase (BTK) Inhibitor ) ( MEK Inhibitor )
|
| Group 10 (PTCH1)
Participants receive vismodegib - dosage, frequency and duration per label PTCH1 deletion or inactivating mutations |
Drug: Vismodegib
Other Name: Erivedge |
| Group 11 (KRAS, NRAS and BRAF)
Participants receive cetuximab - dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype |
Drug: Cetuximab
Other Name: Erbitux
( Immunotherapy , Monoclonal Antibody ) |
| Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)
Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations |
Drug: Dasatinib
Other Name: Sprycel
( Tyrosine Kinase (TK) Inhibitor ) |
| Group 13 (RET,VEGFR1/2/3,KIT,PDGFR?,RAF-1,BRAF
Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR?, RAF-1, BRAF mutations/amplifications |
Drug: Regorafenib
Other Name: Stivarga |
| Group 14 (BRCA1/BRCA2; ATM)
Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions |
Drug: Olaparib
Other Name: Lynparza |
| Group 15 (POLE/POLD1;high mutational load)
Participants receive pembrolizumab- dosage, frequency and duration per label Note: high mutational load defined per protocol |
Drug: Pembrolizumab
Other Name: Keytruda |
Learn more and find the closest trial site here:
TUPAC Clinical Trial
To find eligible clinical trials for your myeloma, click here: Find Myeloma Clinical Trials on SparkCures
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.
